What Belay Diagnostics’ Summit 2.0 results reveal about the future of CNS molecular diagnostics

Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.

Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.